Src, a non-receptor tyrosine kinase, is involved in a number of cancer-related signaling pathways and aberrantly activated in biliary tract cancer (BTC). This study aimed to elucidate the potential role of Src as a therapeutic target in BTC. We tested bosutinib, an orally active c-Src/Abl kinase inhibitor, alone or in combination with cytotoxic agents using nine human BTC cell lines: SNU-245, SNU-308, SNU-478, SNU-869, SNU-1079, SNU-1196, HuCCT1, TFK-1, and EGI-1. Of these, SNU-308 and SNU-478 were relatively sensitive to bosutinib. 
Introduction
Src, a non-receptor tyrosine kinase, is involved in a number of cancer-related signaling pathways including FAK, PI3K, ERK, and STAT3, and promotes the proliferation, adhesion, migration, invasion, and metastasis of cancer cells (1) (2) (3) (4) . Its activity is increased in a variety of malignancies such as lung, skin, colorectal, breast, ovarian, and head and neck cancer (3) (4) (5) (6) ).
In addition, Src activation conferred therapeutic resistance to imatinib treatment for chronic myelogenous leukemia (7, 8), hormone treatment for breast and prostate cancer (9, 10) , and trastuzumab treatment for breast cancer (11, 12) . On the basis of these findings, Src-targeted agents have recently been investigated in preclinical and clinical studies in a variety of malignant diseases.
Biliary tract cancer (BTC) is an relatively uncommon malignancy with a poor prognosis (13) . Most patients are diagnosed at an advanced stage and experience relapse despite radical surgery (14) . Although the recent development of targeted therapeutics has significantly improved the clinical outcome of patients with advanced solid tumors, still there is no validated therapeutic target for advanced BTC and the prognosis of patients with advanced BTC remains still disappointing (15, 16) . In recent years, only gemcitabine plus cisplatin has been established as a standard chemotherapy for BTC patients (17). Therefore, there is still an urgent unmet need for the development of novel therapeutic strategies for the treatment of advanced BTC, based on specific targets on cancer cells.
A recent study demonstrated that Src is also frequently overexpressed in BTC as in other malignant diseases, although its relationship with clinicopathologic parameters or histologic origin was not significant (18). In addition, blocking Src activity by novel Src inhibitors such as saracatinib (AZD-0530) and AZM555130 reduced the proliferative and invasive potential of human BTC cell lines (18, 19) . However, these studies used only a limited number of BTC strategies with other chemotherapeutic agents that are already approved for BTC treatment.
Therefore, further preclinical studies are necessary before designing clinical studies using Src inhibitors.
The aim of our study was to investigate Src as a potential therapeutic target in BTC. We evaluated the therapeutic potential of bosutinib (4-anilino-3-quinolinecarbonitrile, also known as SKI-606) (20), an orally active small molecule c-Src/Abl kinase inhibitor, alone or in combination with cytotoxic agents using in vitro and in vivo models. Equal amounts of proteins were separated on 10% sodium dodecyl sulfate polyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were probed overnight at 4°C with primary antibodies. Primary antibodies against the following molecules were purchased from Cell Signaling Technology (Beverly, MA, USA): Src, phosphorylated Src (Tyr416), FAK, phosphorylated FAK (Tyr397 and Tyr925), AKT, phosphorylated AKT (Ser473), ERK, phosphorylated ERK (Thr202/Tyr204), STAT3, and phosphorylated STAT3 (Tyr705). Anti-Cyclin D, Cyclin E, Cyclin A, Cyclin B, p27, β-catenin, Lamin B, Vimentin, and Snail antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Anti-β-actin antibody was purchased from Sigma-Aldrich. Antibody binding was detected using an enhanced chemiluminescence system according to the manufacturer's protocol (Amersham Biosciences, Piscataway, NJ, USA). Anti-mouse and rabbit secondary antibodies After the cells were treated with 1.0 μM bosutinib, the degree of apoptosis was measured using Annexin V-FITC and PI double-staining according to the protocols of the manufacturer (BD Biosciences). The cells were analyzed using a FACS Calibur flow cytometer (BD Biosciences). Early apoptosis was defined as Annexin V-FITC-positive and PI-negative, while late apoptosis was Annexin V-FITC-and PI-positive. Results are expressed as the mean value of three independent experiments.
Migration and invasion assays
For the migration assay, cells were grown as monolayers in 6-well culture plates. After 24h, confluent monolayers were gently scratched with a sterile 200-μL pipette tip. The plates were washed with phosphate-buffered saline, and then DMSO or 0.1 μM or 1.0 μM bosutinib was added to the wells in medium. After 72 h for SNU-308 cells and 24h for SNU-478 cells, cell movement back into the area of the scratch was recorded by light microscopy. Cell migration was measured in 10 randomly selected microscopic fields for each experiment. Three independent experiments were performed for each condition.
The cell invasion assay was performed using a Cytoselect 24-well cell invasion assay kit (Cell Biolabs, Inc., San Diego, CA, USA). The kit included polycarbonate membrane inserts (8-μm pore size). The upper surface of the insert membrane was coated with a uniform layer of dried murine laminin I matrix. Cells were serum-starved for 24 h then a cell suspension containing 1 × 10 6 cells/mL in serum-free media alone or serum-free media with 1.0 μM of bosutinib was added to the inside of each insert. Each insert was then transferred to a lower well of the plate filled with media containing 20% fetal bovine serum. After incubation for 24 h, the invading cells were stained and extracted, and then quantified by measuring the absorbance at 560 nm with a VersaMax microplate reader (Molecular Devices). The data presented are representative of two independent experiments. 
In vivo study
Animal experiments were performed at the Biomedical Center for Animal Resource Development of Seoul National University, Seoul, Korea, according to the institutional guidelines with prior approval from the institutional animal care and use committee. Of SNU-308 and SNU-478 cell lines that were sensitive to bosutinib in this study, we used the 
Statistical analysis
Experimental data were expressed as the mean ± standard error (SE) and compared using the Student's t-test. Data were analyzed and displayed using SigmaPlot software (Systat Software, Inc.). All statistical tests were two-sided, with significance defined as P < 0.05. Table 1 ). In contrast, TFK-1 cells were relatively resistant to bosutinib with an IC 50 value of 4.45 μM. In a threedimensional culture system, bosutinib also showed an anti-proliferative effect that was dose dependent in both SNU-308 and SNU-478 cells (Fig. 1B) .
Next, western blot analysis was performed to evaluate the effect of bosutinib on the downstream signaling pathways of Src ( 
Inhibition of Src by bosutinib induces G1 cell-cycle arrest in sensitive BTC cell lines
The effects of bosutinib on the cell-cycle of SNU-308, SNU-478, and TFK-1 cells were evaluated using flow cytometry. Bosutinib significantly increased G1 cell-cycle arrest in a dose-dependent manner in both SNU-308 and SNU-478 cells ( was significantly increased by bosutinib treatment in SNU-478 cells (p = 0.008), and showed a tendency to be increased in SNU-308 cells with borderline significance (p = 0.062). In TFK-1 cells, G1 cell-cycle arrest was significantly increased after 1 μM bosutinib treatment but this was not observed at lower concentrations. The sub-G1 fraction in TFK-1 cells was not significantly increased by bosutinib treatment (p = 0.572). After 1 μM bosutinib treatment for 48h, the Annexin V-FITC/PI stain revealed that bosutinib significantly induced both early and late apoptosis in SNU-308 and SNU-478 cells (Fig. 2B) . However, the tendency was not apparent in TFK-1 cells. Bosutinib decreased Cyclin D, Cyclin E, Cyclin A, and Cyclin B expression, and increased p27 expression in both SNU-308 and SNU-478 cells, but not in TFK-1 cells (Fig. 2C ). Of note, the nuclear expression of p27 was significantly increased in both SNU-308 and SNU-478 cells, but not in TFK-1 cells (Fig. 2D) .
Bosutinib inhibits the migration and invasion of BTC cells
Migration and invasion assays were performed to determine the effect of bosutinib on the migration and invasion activity of BTC cells. The migration assays indicated that bosutinib significantly inhibited the migratory activity of both SNU-308 and SNU-478 cells (Fig. 3A) .
Furthermore, bosutinib significantly inhibited the invasive activity of SNU-478 cells (Fig.   3B ).
Next, we performed western blot analysis to investigate the effect of bosutinib on the expression levels of proteins related to epithelial-mesenchymal transition (EMT) in SNU-308 and SNU-478 cells. Bosutinib did not influence the expression levels of E-cadherin and β-catenin in both cell lines. However, Vimentin levels were slightly decreased and Snail expression was potently abrogated by bosutinib in a dose-dependent manner (Fig. 3C) . (Fig. 4A) . The migratory effects of cytotoxic agents were potentiated by the addition of bosutinib (Fig 4B) .
In addition, combination treatment of bosutinib with gemcitabine or cisplatin for 72 h significantly inhibited the migration of SNU-478 cells when compared with bosutinib monotherapy. In SNU-478 cells, combination treatment of bosutinib with gemcitabine or cisplatin further abrogated Src phosphorylation compared with bosutinib alone, and further downregulated Vimentin and Snail expression compared with bosutinib, gemcitabine, or cisplatin alone (Fig. 4C) .
Src inhibition has potent antitumor effects in a xenograft model
A SNU-478 xenograft model using female Balb/c athymic nude mice demonstrated that bosutinib alone significantly delayed tumor growth compared with controls (Fig. 5A ).
Bosutinib combined with gemcitabine or cisplatin showed significantly more potent antitumor effects when compared with bosutinib, gemcitabine, or cisplatin monotherapy.
Moreover, the combination treatment did not significantly influence the body weight of mice (data not shown).
Tumors treated with bosutinib alone exhibited an apparent decrease in cell proliferation by Ki-67 assays and an apparent increase in apoptosis by TUNEL assays (Fig. 5B) 
further increased TUNEL expression. In tumor lysates, the phosphorylation of Src and STAT3 was downregulated by bosutinib monotherapy. Moreover, when bosutinib was combined with gemcitabine, a greater decrease in Src and STAT3 phosphorylation was observed (Fig. 5C) . 
Discussion
Our data suggested that Src might be a potential therapeutic target in BTC. A previous study indicated that about 80% of BTC specimens expressed an activated Src protein similar to other malignancies (3-6, 18). In our study, a total of nine BTC cell lines were tested, and the Cell-cycle analysis demonstrated that bosutinib induced G1 arrest and increased the sub-G1 fraction in a dose-dependent manner in SNU-308 and SNU-478 cells. Bosutinib decreased Cyclin D, Cyclin E, Cyclin A, and Cyclin B expression, and increased p27 expression in both sensitive BTC cell lines. In particular, the nuclear stabilization of p27 was also observed after bosutinib treatment, which has been suggested to be a mechanism of apoptosis induced by the Src inhibitor (34). Moreover, bosutinib monotherapy demonstrated potent anti-migratory and anti-invasive activity against BTC cell lines, and downregulated the expression of proteins related to EMT, which is associated with cancer progression and 
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